ERCC1 and Non–Small-Cell Lung Cancer

Publisher Website
Google Scholar
Abstract
Zheng et al. (Feb. 22 issue)1 conclude that the excision repair cross-complementation group 1 (ERCC1) protein is a determinant of survival after surgical treatment of early-stage non–small-cell lung cancer. The ERCC1 protein associates with the xeroderma pigmentosum group F (XPF) protein to form a nuclease that functions in DNA repair.2 The level of ERCC1 protein was proposed as a useful predictor of response to cisplatin-based chemotherapy and clinical outcome,3 on the basis of immunohistochemical staining of tumors with the use of the monoclonal antibody 8F1. To our knowledge, however, no controlled experiments demonstrating the specificity of this antibody have been reported.